Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although software-as-a-service business Salesforce.com ...

We recently compiled a list of the Why These 24 Stocks Are Skyrocketing. In this article, we are going to take a look at where Chimerix, Inc. (NASDAQ:CMRX) stands against the other stocks. One of the ...

Chimerix CMRX, along with its earnings release, announced that it is planning to limit its investment in a retrospective Natural Disease History (NDH) study of recurrent H3 K27M-mutant glioma to ...

In other recent news, Chimerix announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application for dordaviprone, a potential treatment for recurrent H3 K27M-mutant ...

On Monday, Chimerix (NASDAQ:CMRX) announced that, following extensive dialogue with the FDA, the company plans to submit a complete New Drug Application (NDA) seeking accelerated approval for ...

- Small Business Administration Rules that SIGA Technologies is Not a Small Business, Rendering It Ineligible for BARDA Contract RESEARCH TRIANGLE PARK, NC, November 7, 2010 - Chimerix, Inc., a ...

Chimerix meets financial expectations during Q2, 2023 earnings call. Investment thesis for Chimerix focuses on its ONC201 study expected to read out in 2026. Company has high risk of loss despite ...

Chimerix took quite a skid as it passed into the danger zone. Earnings for Q4, 2022 support an ongoing bull thesis for Chimerix. Wall Street Analysts have been strongly supportive of CMRX in the past ...

Chimerix Inc (NASDAQ: NASDAQ: CMRX) stock has reached a new 52-week high, touching $3.44 amidst a remarkable year of growth. The biopharmaceutical company, known for its antiviral therapies and ...

Just two days after its most recent and biggest fundraising, VC-backed pharmaceutical company Chimerix Inc. has locked in millions more in the form of a federal contract. The Biomedical Advanced ...

Chimerix, a biopharmaceutical company, announced that the New Drug Application (NDA) for its drug Dordaviprone, aimed at treating recurrent H3 K27M-mutant diffuse glioma, is under review with a ...

Chimerix also updated its Officer Severance Benefit Plan, extending its term for an additional three years from November 2024. This corporate governance move ensures clear expectations for the company ...